Myelodysplastic Syndromes in the Elderly: Treatment Options and Personalized Management (Q40420210)

20 September 2017

Myelodysplastic Syndromes in the Elderly: Treatment Options and Personalized Management (English)

1 reference

20 September 2017

3

Reinhard Stauder

1 reference

20 September 2017

Sonja Burgstaller

1

1 reference

PubMed ID

26476843

20 September 2017

Petra Wiesinger

series ordinal

2

1 reference

20 September 2017

17 October 2015

1 reference

20 September 2017

1 reference

20 September 2017

32

1 reference

20 September 2017

11

1 reference

20 September 2017

891-905

1 reference

https://scigraph.springernature.com/pub.10.1007/s40266-015-0312-7

20 September 2017

0 references

cites work

Myelodysplastic Syndromes

1 reference

https://api.crossref.org/works/10.1007%2FS40266-015-0312-7

Prognostic impact of age and gender in 897 untreated patients with primary myelodysplastic syndromes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-015-0312-7

Validation of the revised international prognostic scoring system (IPSS-R) in patients with lower-risk myelodysplastic syndromes: a report from the prospective European LeukaemiaNet MDS (EUMDS) registry.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-015-0312-7

Incidence and prevalence of myelodysplastic syndromes: data from the Düsseldorf MDS-registry

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-015-0312-7

The incidence of myelodysplastic syndromes in Western Greece is increasing.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-015-0312-7

Prevalence of anaemia in older persons: systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-015-0312-7

Prevalence of anemia in persons 65 years and older in the United States: evidence for a high rate of unexplained anemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-015-0312-7

A prospective study of anemia status, hemoglobin concentration, and mortality in an elderly cohort: the Cardiovascular Health Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-015-0312-7

Association of mild anemia with hospitalization and mortality in the elderly: the Health and Anemia population-based study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-015-0312-7

Impact of anemia on mortality, cognition, and function in community-dwelling elderly

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-015-0312-7

Effect of anemia and comorbidity on functional status and mortality in old age: results from the Leiden 85-plus Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-015-0312-7

Prevalence, incidence and types of mild anemia in the elderly: the "Health and Anemia" population-based study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-015-0312-7

The frequency and clinical significance of thrombocytopenia complicating critical illness: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-015-0312-7

Platelet counts and haemorrhagic diathesis in patients with myelodysplastic syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-015-0312-7

Prevalence of neutropenia in the U.S. population: age, sex, smoking status, and ethnic differences

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-015-0312-7

A prognostic score for patients with lower risk myelodysplastic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-015-0312-7

Incidence and clinical complications of myelodysplastic syndromes among United States Medicare beneficiaries

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-015-0312-7

Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNet

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-015-0312-7

Revised international prognostic scoring system for myelodysplastic syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-015-0312-7

Validation of WHO classification-based Prognostic Scoring System (WPSS) for myelodysplastic syndromes and comparison with the revised International Prognostic Scoring System (IPSS-R). A study of the International Working Group for Prognosis in Myelo

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-015-0312-7

Validation of cytogenetic risk groups according to International Prognostic Scoring Systems by peripheral blood CD34+FISH: results from a German diagnostic study in comparison with an international control group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-015-0312-7

Identification of distinct prognostic subgroups in low- and intermediate-1-risk myelodysplastic syndromes by flow cytometry

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-015-0312-7

Definitions and standards in the diagnosis and treatment of the myelodysplastic syndromes: Consensus statements and report from a working conference

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-015-0312-7

Coalesced multicentric analysis of 2,351 patients with myelodysplastic syndromes indicates an underestimation of poor-risk cytogenetics of myelodysplastic syndromes in the international prognostic scoring system

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-015-0312-7

Impact of the degree of anemia on the outcome of patients with myelodysplastic syndrome and its integration into the WHO classification-based Prognostic Scoring System (WPSS)

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-015-0312-7

Cancer screening in elderly patients: a framework for individualized decision making

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-015-0312-7

Clustering of comorbidities is related to age and sex and impacts clinical outcome in myelodysplastic syndromes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-015-0312-7

Comorbidity as prognostic variable in MDS: comparative evaluation of the HCT-CI and CCI in a core dataset of 419 patients of the Austrian MDS Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-015-0312-7

Impact of age and comorbidity in myelodysplastic syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-015-0312-7

Association of comorbidities with overall survival in myelodysplastic syndrome: development of a prognostic model

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-015-0312-7

Risk stratification based on both disease status and extra-hematologic comorbidities in patients with myelodysplastic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-015-0312-7

Evaluation of comorbidities at diagnosis predicts outcome in myelodysplastic syndrome patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-015-0312-7

Comorbidities and survival in a large cohort of patients with newly diagnosed myelodysplastic syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-015-0312-7

The timed "Up & Go": a test of basic functional mobility for frail elderly persons

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-015-0312-7

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-015-0312-7

Screening older cancer patients: first evaluation of the G-8 geriatric screening tool.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-015-0312-7

The G8 screening tool detects relevant geriatric impairments and predicts survival in elderly patients with a haematological malignancy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-015-0312-7

The relevance of a geriatric assessment for elderly patients with a haematological malignancy--a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-015-0312-7

Parameters detected by geriatric and quality of life assessment in 195 older patients with myelodysplastic syndromes and acute myeloid leukemia are highly predictive for outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-015-0312-7

Geriatric assessment is associated with completion of chemotherapy, toxicity, and survival in older adults with cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-015-0312-7

Acute myeloid leukemia and myelodysplastic syndromes in older adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-015-0312-7

The challenge of individualised risk assessment and therapy planning in elderly high-risk myelodysplastic syndromes (MDS) patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-015-0312-7

Prevalence, severity and correlates of fatigue in newly diagnosed patients with myelodysplastic syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-015-0312-7

On-going clinical trials for elderly patients with a hematological malignancy: are we addressing the right end points?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-015-0312-7

Myelodysplastic syndromes: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-015-0312-7

The ASH Choosing Wisely®campaign: five hematologic tests and treatments to question.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-015-0312-7

Evaluation of myocardial iron by magnetic resonance imaging during iron chelation therapy with deferrioxamine: indication of close relation between myocardial iron content and chelatable iron pool.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-015-0312-7

Does iron chelation therapy improve survival in regularly transfused lower risk MDS patients? A multicenter study by the GFM (Groupe Francophone des Myélodysplasies).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-015-0312-7

An increase in hemoglobin, platelets and white blood cells levels by iron chelation as single treatment in multitransfused patients with myelodysplastic syndromes: clinical evidences and possible biological mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-015-0312-7

Iron overload in myelodysplastic syndromes (MDS) - diagnosis, management, and response criteria: a proposal of the Austrian MDS platform

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-015-0312-7

Prognostic impact of elevated pretransplantation serum ferritin in patients undergoing myeloablative stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-015-0312-7

Efficacy and safety of erythropoiesis-stimulating proteins in myelodysplastic syndrome: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-015-0312-7

An assessment of erythroid response to epoetin alpha as a single agent versus in combination with granulocyte- or granulocyte-macrophage-colony-stimulating factor in myelodysplastic syndromes using a meta-analysis approach

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-015-0312-7

Erythropoiesis-stimulating agents in the treatment of anemia in myelodysplastic syndromes: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-015-0312-7

Myelodysplastic syndromes: 2014 update on diagnosis, risk-stratification, and management

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-015-0312-7

Erythroid response to treatment with G-CSF plus erythropoietin for the anaemia of patients with myelodysplastic syndromes: proposal for a predictive model

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-015-0312-7

A validated decision model for treating the anaemia of myelodysplastic syndromes with erythropoietin + granulocyte colony-stimulating factor: significant effects on quality of life

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-015-0312-7

Prognostic impact of severe thrombocytopenia in low-risk myelodysplastic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-015-0312-7

Platelet transfusion - the new immunology of an old therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-015-0312-7

Thrombopoiesis-stimulating agents and myelodysplastic syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-015-0312-7

Phase 2 study of romiplostim in patients with low- or intermediate-risk myelodysplastic syndrome receiving azacitidine therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-015-0312-7

Safety and efficacy of romiplostim in patients with lower-risk myelodysplastic syndrome and thrombocytopenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-015-0312-7

Myeloma as a model for the process of metastasis: implications for therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-015-0312-7

Results of a randomized, double-blind study of romiplostim versus placebo in patients with low/intermediate-1-risk myelodysplastic syndrome and thrombocytopenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-015-0312-7

Eltrombopag modulates reactive oxygen species and decreases acute myeloid leukemia cell survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-015-0312-7

Treatment of myelodysplastic syndromes with 5q deletion before the lenalidomide era; the GFM experience with EPO and thalidomide

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-015-0312-7

Extended survival and reduced risk of AML progression in erythroid-responsive lenalidomide-treated patients with lower-risk del(5q) MDS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-015-0312-7

TP53 mutations in low-risk myelodysplastic syndromes with del(5q) predict disease progression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-015-0312-7

Lenalidomide: a review of its use in patients with transfusion-dependent anaemia due to low- or intermediate-1-risk myelodysplastic syndrome associated with 5q chromosome deletion

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-015-0312-7

A randomized phase 3 study of lenalidomide versus placebo in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with del5q.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-015-0312-7

Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1 risk myelodysplastic syndromes with karyotypes other than deletion 5q.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-015-0312-7

Lenalidomide in lower-risk myelodysplastic syndromes with karyotypes other than deletion 5q and refractory to erythropoiesis-stimulating agents.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-015-0312-7

Combined treatment with lenalidomide and epoetin alfa in lower-risk patients with myelodysplastic syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-015-0312-7

Factors affecting response and survival in patients with myelodysplasia treated with immunosuppressive therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-015-0312-7

Hematologic response to three alternative dosing schedules of azacitidine in patients with myelodysplastic syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-015-0312-7

Significant improvement in survival after allogeneic hematopoietic cell transplantation during a period of significantly increased use, older recipient age, and use of unrelated donors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-015-0312-7

Effect of age on outcome of reduced-intensity hematopoietic cell transplantation for older patients with acute myeloid leukemia in first complete remission or with myelodysplastic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-015-0312-7

Transplant for MDS: challenges and emerging strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-015-0312-7

Treatment of older patients with high-risk myelodysplastic syndromes (MDS): the emerging role of allogeneic hematopoietic stem cell transplantation (Allo HSCT).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-015-0312-7

Comparing morbidity and mortality of HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative and myeloablative conditioning: influence of pretransplantation comorbidities

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-015-0312-7

The hematopoietic stem cell transplantation comorbidity index is of prognostic relevance for patients with myelodysplastic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-015-0312-7

A new method of classifying prognostic comorbidity in longitudinal studies: development and validation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-015-0312-7

Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-015-0312-7

Pretransplant comorbidities predict severity of acute graft-versus-host disease and subsequent mortality.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-015-0312-7

Allogeneic hematopoietic cell transplantation for acute myeloid leukemia in older adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-015-0312-7

AML associated with previous cytotoxic therapy, MDS or myeloproliferative disorders: results from the MRC's 9th AML trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-015-0312-7

A critical appraisal of low-dose cytosine arabinoside in patients with acute non-lymphocytic leukemia and myelodysplastic syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-015-0312-7

Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-015-0312-7

Effects of azacitidine compared with conventional care regimens in elderly (≥ 75 years) patients with higher-risk myelodysplastic syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-015-0312-7

A multivariate analysis of the relationship between response and survival among patients with higher-risk myelodysplastic syndromes treated within azacitidine or conventional care regimens in the randomized AZA-001 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-015-0312-7

Phase I study of oral azacitidine in myelodysplastic syndromes, chronic myelomonocytic leukemia, and acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-015-0312-7

Platelet count doubling after the first cycle of azacitidine therapy predicts eventual response and survival in patients with myelodysplastic syndromes and oligoblastic acute myeloid leukaemia but does not add to prognostic utility of the revised IP

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-015-0312-7

Platelet doubling after the first azacitidine cycle is a promising predictor for response in myelodysplastic syndromes (MDS), chronic myelomonocytic leukaemia (CMML) and acute myeloid leukaemia (AML) patients in the Dutch azacitidine compassionate n

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-015-0312-7

TET2 mutations predict response to hypomethylating agents in myelodysplastic syndrome patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-015-0312-7

Prognostic factors for response and overall survival in 282 patients with higher-risk myelodysplastic syndromes treated with azacitidine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-015-0312-7

Outcome of high-risk myelodysplastic syndrome after azacitidine treatment failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-015-0312-7

Phase I clinical trial of oral rigosertib in patients with myelodysplastic syndromes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-015-0312-7

Acute graft-versus-host disease: more than just alloreactivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-015-0312-7

Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-015-0312-7

Comparative analysis between azacitidine and decitabine for the treatment of myelodysplastic syndromes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-015-0312-7

Treatment of poor-risk myelodysplastic syndromes and acute myeloid leukemia with a combination of 5-azacytidine and valproic acid

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-015-0312-7

Prolonged responses in patients with MDS and CMML treated with azacitidine and etanercept

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-015-0312-7

Safety and clinical activity of the combination of 5-azacytidine, valproic acid, and all-trans retinoic acid in acute myeloid leukemia and myelodysplastic syndrome

21 January 2018

1 reference

12 December 2020

Immunosuppressive therapy for patients with myelodysplastic syndrome: a prospective randomized multicenter phase III trial comparing antithymocyte globulin plus cyclosporine with best supportive care--SAKK 33/99

1 reference

12 December 2020

Proteasome inhibition in myelodysplastic syndromes and acute myelogenous leukemia cell lines

1 reference

12 December 2020

Proposed score for survival of patients with myelodysplastic syndromes.

1 reference

12 December 2020

A simple method to predict response to immunosuppressive therapy in patients with myelodysplastic syndrome

1 reference

12 December 2020

New insights into the prognostic impact of the karyotype in MDS and correlation with subtypes: evidence from a core dataset of 2124 patients

1 reference

12 December 2020

Myelodysplastic syndromes: incidence and survival in the United States

1 reference

12 December 2020

Causes of initial remission induction failure in acute myelogenous leukemia.

1 reference

12 December 2020

Prevalence and possible causes of anemia in the elderly: a cross-sectional analysis of a large European university hospital cohort

1 reference

12 December 2020

Clinical utility of lenalidomide in the treatment of myelodysplastic syndromes

1 reference

12 December 2020

Treatment of therapy-related leukemia and myelodysplastic syndrome.

1 reference

12 December 2020

Allogeneic hematopoietic stem-cell transplantation for patients 50 years or older with myelodysplastic syndromes or secondary acute myeloid leukemia

1 reference

12 December 2020

FUNCTIONAL EVALUATION: THE BARTHEL INDEX

1 reference

12 December 2020

Effectiveness and safety of different azacitidine dosage regimens in patients with myelodysplastic syndromes or acute myeloid leukemia

1 reference

12 December 2020

Management of cancer in the older person: a practical approach

1 reference

12 December 2020

[Malnutrition in the elderly: the Mini Nutritional Assessment (MNA)]

1 reference

12 December 2020

Myelodysplastic syndromes

1 reference

12 December 2020

Comparison of 7-day azacitidine and 5-day decitabine for treating myelodysplastic syndrome

1 reference

12 December 2020

Impact of TET2 mutations on response rate to azacitidine in myelodysplastic syndromes and low blast count acute myeloid leukemias

1 reference

12 December 2020

Assessment of older people: self-maintaining and instrumental activities of daily living

1 reference

12 December 2020

Prevalence and causes of anaemia in a geriatric hospitalized population

1 reference

12 December 2020

International scoring system for evaluating prognosis in myelodysplastic syndromes

1 reference

12 December 2020

Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes

1 reference

12 December 2020

Deferasirox reduces serum ferritin and labile plasma iron in RBC transfusion-dependent patients with myelodysplastic syndrome

1 reference

12 December 2020

Low-dose ara-C in acute nonlymphocytic leukemia and myelodysplastic syndromes: a review of 20 years' experience

1 reference

12 December 2020

10.1007/S40266-015-0312-7

Identifiers

DOI

1 reference

PubMed ID

26476843

Dimensions Publication ID

20 September 2017

0 references

1 reference

PubMed ID

26476843